Status:
COMPLETED
Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Breast Cancer Stage IV
Eligibility:
FEMALE
18+ years
Brief Summary
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with CDKi in patients with HR-positive, HER2-negative advanced breast cance...
Detailed Description
Patients This will be a retrospective analysis of patients with histologically confirmed HR-positive, HER2-negative advanced (recurrent or metastatic) breast cancer. The investigators will use data fr...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 18 years or older
- Αny menopausal status is allowed
- HR-positive/HER2-negative advanced breast cancer
- Patients treated with CDKi in combination with endocrine therapy for their advanced breast cancer
- Combinations of CDKi with any endocrine therapy are allowed
- More than two months of treatment with a CDKi is mandatory
- Exclusion criteria:
- • Treatment with CDKi as (neo)adjuvant treatment
Exclusion
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 2 2021
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT04133207
Start Date
January 1 2019
End Date
January 2 2021
Last Update
February 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hellenic Oncology Cooperative Group
Athens, Greece